Of 52 tumor samples from the population evaluable by FoundationOne®CDx, 39 (75.0%) and 13 (25.0%) patients exhibited BRCA1 and BRCA2 mutations, respectively; 1 (1.9%) patient exhibited mutations in both genes; and 1 (1.9%) patient had mutations in neither (Supplementary Table S2). Here, BRCA2 is linked to neoplasm.